Literature DB >> 29739895

Long-Term Survival Rates of Patients with Stage III-IV Hodgkin Lymphoma According to Age, Sex, Race, and Socioeconomic Status, 1984-2013.

Yushi Li1, Huanhuan Sun1, Yan Yan1, Tiantian Sun2, Shuncong Wang1, Haiqing Ma3.   

Abstract

BACKGROUND: Long-term survival rates for patients with stage III-IV Hodgkin lymphoma, or advanced Hodgkin lymphoma (aHL), have increased substantially since the 1960s. Because large-scale research of aHL is rare, we aimed to demonstrate the differences in incidence and survival of aHL according to four patient variables in recent decades, with a focus on the outcomes of treatment of aHL and the advancement of public health care.
MATERIALS AND METHODS: Data on aHL cases diagnosed during 1984-2013 were extracted from the Surveillance, Epidemiology, and End Results Program database. Relative survival, Kaplan-Meier, and Cox proportional hazards regression analyses were performed to identify prognosis indicators for aHL.
RESULTS: The incidence rates for aHL were 1.1, 0.8, and 1.0 per 100,000 in the first, second, and third decades, respectively, during 1984-2013. The 120-month relative survival rate improved continuously in each decade from 58.5% to 64.6% to 72.1%. In addition, disparities in the 120-month relative survival rate between male and female patients and among patients of different races narrowed over time. The difference in long-term survival rate between the poor (medium and high poverty) and rich (low poverty) groups narrowed across the 3 decades.
CONCLUSION: The long-term survival rate for patients with aHL increased in each decade, whereas survival rate disparities according to sex, race, and socioeconomic status narrowed, except for older patients aged >60 years and the high-poverty group. IMPLICATIONS FOR PRACTICE: Long-term survival rates of patients with advanced Hodgkin lymphoma were elaborated in this article. The disparities according to sex, race, and socioeconomic status of survival condition were analyzed and showed the development of the public health care system and modern medicine technology. © AlphaMed Press 2018.

Entities:  

Keywords:  Incidence; Period analysis; Relative survival; Stage III–IV Hodgkin lymphoma

Mesh:

Year:  2018        PMID: 29739895      PMCID: PMC6291323          DOI: 10.1634/theoncologist.2017-0541

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  32 in total

Review 1.  Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection.

Authors:  James J Goedert; Mark Bower
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

2.  Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.

Authors:  Evert M Noordijk; Patrice Carde; Noëlle Dupouy; Anton Hagenbeek; Augustinus D G Krol; Johanna C Kluin-Nelemans; Umberto Tirelli; Mathieu Monconduit; José Thomas; Houchingue Eghbali; Berthe M P Aleman; Jacques Bosq; Marjeta Vovk; Tom A M Verschueren; Anne-Marie Pény; Théodore Girinsky; John M M Raemaekers; Michel Henry-Amar
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

3.  An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.

Authors:  S Gottschalk; C Y Ng; M Perez; C A Smith; C Sample; M K Brenner; H E Heslop; C M Rooney
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

4.  Perinatal and family risk factors for Hodgkin lymphoma in childhood through young adulthood.

Authors:  Casey Crump; Kristina Sundquist; Weiva Sieh; Marilyn A Winkleby; Jan Sundquist
Journal:  Am J Epidemiol       Date:  2012-11-21       Impact factor: 4.897

Review 5.  Treatment of early-stage Hodgkin lymphoma.

Authors:  Andreas Engert; John Raemaekers
Journal:  Semin Hematol       Date:  2016-05-12       Impact factor: 3.851

6.  Hodgkin lymphoma, version 2.2015.

Authors:  Richard T Hoppe; Ranjana H Advani; Weiyun Z Ai; Richard F Ambinder; Patricia Aoun; Celeste M Bello; Cecil M Benitez; Philip J Bierman; Kristie A Blum; Robert Chen; Bouthaina Dabaja; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Ephraim P Hochberg; Jiayi Huang; Patrick B Johnston; Nadia Khan; David G Maloney; Peter M Mauch; Monika Metzger; Joseph O Moore; David Morgan; Craig H Moskowitz; Carolyn Mulroney; Matthew Poppe; Rachel Rabinovitch; Stuart Seropian; Christina Tsien; Jane N Winter; Joachim Yahalom; Jennifer L Burns; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2015-05       Impact factor: 11.908

Review 7.  Checkpoint inhibition and cellular immunotherapy in lymphoma.

Authors:  Premal Lulla; Helen E Heslop
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

8.  Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.

Authors:  Boris Böll; Helen Goergen; Karolin Behringer; Paul J Bröckelmann; Felicitas Hitz; Andrea Kerkhoff; Richard Greil; Bastian von Tresckow; Dennis A Eichenauer; Carolin Bürkle; Sven Borchmann; Michael Fuchs; Volker Diehl; Andreas Engert; Peter Borchmann
Journal:  Blood       Date:  2016-02-01       Impact factor: 22.113

9.  Long-term survival after treatment for Hodgkin's disease (1973-2002): improved survival with successive 10-year cohorts.

Authors:  E M Bessell; G Bouliotis; S Armstrong; J Baddeley; A P Haynes; S O'Connor; H Nicholls-Elliott; M Bradley
Journal:  Br J Cancer       Date:  2012-06-19       Impact factor: 7.640

10.  Improved survival time trends in Hodgkin's lymphoma.

Authors:  Matthew Koshy; Andrew Fairchild; Christina H Son; Usama Mahmood
Journal:  Cancer Med       Date:  2016-03-21       Impact factor: 4.452

View more
  6 in total

Review 1.  Current Treatment Options for Older Patients with Hodgkin Lymphoma.

Authors:  Jordan Carter; Kevin A David; Athena Kritharis; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

2.  Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database.

Authors:  Guru Subramanian Guru Murthy; Aniko Szabo; Mehdi Hamadani; Timothy S Fenske; Nirav N Shah
Journal:  Oncologist       Date:  2019-08-29

Review 3.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

4.  Survival analysis of 8785 malignant lymphoma cases in the oral and nasal cavities in the USA: a cohort study.

Authors:  Feifei Jiang; Ai-Hui Yan
Journal:  BMJ Open       Date:  2021-12-15       Impact factor: 2.692

5.  Patterns of National Cancer Institute-Sponsored Clinical Trial Enrollment in Black Adolescents and Young Adults.

Authors:  Michael Roth; Melissa Beauchemin; Justine M Kahn; Archie Bleyer
Journal:  Cancer Med       Date:  2021-09-30       Impact factor: 4.452

6.  Epidemiological Trends of Head and Neck Cancer: A Population-Based Study.

Authors:  Kangwen Guo; Weiliang Xiao; Xinggui Chen; Zhenying Zhao; Yuanxiong Lin; Ge Chen
Journal:  Biomed Res Int       Date:  2021-07-14       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.